Company intelligence / Profile preview

mPOD

New York City, New York, United Statesmpod.io ↗

Ownership: Private
Development stage: Preclinical

Overview

mPOD has developed a rapid diagnostic test for COVID‑19 that delivers results in under 15 minutes. The company aims to expand its aptamer-based detection suite to cover additional infectious diseases. It has received NIH funding and support from BARDA as part of the Blue Knight program at Johnson & Johnson Innovation JLABS in New York City. No published clinical trial results are available yet; the company appears to be in early validation or pilot deployment stages[1][2].

Therapeutic areas: Infectious Diseases
Modalities: Aptamer-based diagnostics (no evidence of therapeutic drug development)
Industry: Molecular Diagnostics

Partnerships

Johnson & Johnson Innovation JLABS @ NYC (incubator/support)[1][2]Biomedical Advanced Research and Development Authority (BARDA) via Blue Knight program[2]

Beyond the preview

Go deeper on mPOD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mPOD.

Explore the full profile